Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Fulvestrant
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2022-10-12

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 72

Registration Number: NCT05574881

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Advanced/ Metastatic Her-2 Positive Breast Cancer

Interventions: Drug: GQ1001+pyrotinib
Drug: pyrotinib+capecitabine

First Posted Date: 2022-10-12

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 75

Registration Number: NCT05575804

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Acute Health Effects of High Temperature Exposure

Not Applicable

Active, not recruiting

Conditions: Cognitive Function
Respiratory System
Cardiovascular System

Interventions: Other: moderate temperature (22℃) group
Other: high temperature (32℃) group

First Posted Date: 2022-10-12

Last Posted Date: 2024-10-01

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT05575752

Locations: 🇨🇳
Department of Environmental Health, School of Public Health, Fudan University, Shanghai, Shanghai, China

Peri-operative Foot CT Perfusion in CLI Patients

Active, not recruiting

Conditions: Critical Limb Ischemia

First Posted Date: 2022-10-12

Last Posted Date: 2022-10-12

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT05575778

Locations: 🇨🇳
Hua Dong Hospital Affiliated to Fu Dan University, Shanghai, China

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Completed

Conditions: Breast Cancer

Interventions: Drug: Pertuzumab Plus Trastuzumab
Drug: Pyrotinib Plus Trastuzumab

First Posted Date: 2022-10-10

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 333

Registration Number: NCT05572645

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Rechallenge of ADCs in MBC Patients

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: ADC

First Posted Date: 2022-10-07

Last Posted Date: 2024-10-21

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT05571618

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients

Not Applicable

Recruiting

Conditions: Luteal Phase Support
Idiopathic Hypogonadotropic Hypogonadism
Luteal Phase Deficiency

Interventions: Drug: Additional hCG injection
Drug: estrogen and dydrogesterone

First Posted Date: 2022-10-06

Last Posted Date: 2024-08-07

Lead Sponsor: Fudan University

Target Recruit Count: 46

Registration Number: NCT05569577

Locations: 🇨🇳
OB & GYN Hospital of Fudan University, Shanghai, Shanghai, China
🇨🇳
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China

The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib+ chemotherapy
Drug: Bevacizumab+ chemotherapy

First Posted Date: 2022-09-27

Last Posted Date: 2023-08-30

Lead Sponsor: Fudan University

Target Recruit Count: 116

Registration Number: NCT05555901

Locations: 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, Hebei, China

and more 10 locations

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E）

Phase 2

Recruiting

Conditions: Early Low Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: Oxaliplatin
Radiation: Short-course radiotherapy

First Posted Date: 2022-09-27

Last Posted Date: 2023-09-18

Lead Sponsor: Fudan University

Target Recruit Count: 34

Registration Number: NCT05555888

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Health-promoting Lifestyle in a Genetic Counseling Clinic

Completed

Conditions: Genetic Testing
Breast Cancer

Interventions: Genetic: genetic testing

First Posted Date: 2022-09-19

Last Posted Date: 2022-09-19

Lead Sponsor: Fudan University

Target Recruit Count: 140

Registration Number: NCT05545254

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy